Avida Global has announced another promising development in its move towards becoming a world-leading seed to sale cannabis firm.
The British producer of high-quality medicinal cannabis oils has announced the appointment of Peter Donovan as global commercial director.
In this newly created role, Donovan will be responsible for forging commercial and partnership opportunities globally with an initial focus on the UK and Europe. He starts his new role on Monday 23 August and will report directly to David Kirby, CEO.
Donovan has had a long and established career in the Big Pharma industry.
Most recently, he headed up Business Development at FIGR Brands Europe/Pyxus International where he was responsible for driving sales of CBD raw materials.
He has also held roles at British American Tobacco, where he headed up the company’s Healthcare and Vaping Channel, CBD start up, Always Pure Organics, Pharmexx UK (Celesio GMBH) and Omega Pharma/A Perrigo Company.
Speaking about the appointment, Donovan commented: “Avida Global is a company with integrity and transparency at its core; from the cultivation and production of its oils, to the people who work across all lines of the business, it’s a company that practices what it preaches.
“It’s an exciting time in the medical cannabis sector and I’m proud to be joining a company with such a great ethos and ambition.”
David Kirby, chief executive officer at Avida Global said: “We are extremely pleased to welcome Peter to the Avida Global team. His Big Pharma experience and acute commercial acumen are key as we look to accelerate our partnerships and make our oils available to a wider audience for whom purity and consistency are key.”